HOPE Therapeutics projects HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), announced plans to acquire a network of interventional psychiatry clinics, focusing on ketamine treatments. The acquisition and financing agreements, valued at $30 million, are backed by a qualified lender. The company signed a non-binding Term Sheet for five operational clinics in the Western United States, generating over $10 million in annual revenue.
NRx药品公司的子公司HOPE Therapeutics, Inc. (NASDAQ:NRXP) 宣布计划收购一家侧重于低气温疗法的精神科干预诊所网络。该收购和融资协议总值3000万美元，由一家合格的借款人提供支持。该公司与一家位于美国西部的运营诊所签订了一份非约束性期限协议表，年收入超过1000万美元。
The clinics will focus on treating conditions like suicidal depression, treatment-resistant depression (TRD), and PTSD. HOPE Therapeutics aims to create a unified, patient-centered approach, combining pharmaceutical therapies and FDA-approved technologies like Transcranial Magnetic Stimulation (TMS).
这些诊所将侧重于治疗自杀性抑郁症、难治性抑郁症(TRD)和PTSD等疾病。HOPE Therapeutics旨在创建一个统一的、以患者为中心的方法，将药物疗法和FDA批准的技术(如经颅磁刺激)相结合。
Co-CEOs Jonathan Javitt and Matthew Duffy emphasized the importance of this initiative. "We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care."
联席首席执行官Jonathan Javitt和Matthew Duffy强调了这项计划的重要性。“我们很高兴迈出发展网络诊所的关键第一步，以提供最高水平的护理。”
HOPE Therapeutics projects annualized revenues of $100 million by mid-2025 through continued clinic acquisitions and anticipates potential operations in the United States, France, and the United Kingdom.
HOPE Therapeutics预计到2025年中期实现年收入1亿美元，并通过继续收购诊所来扩大业务，并预计在美国、法国和英国进行潜在的运营。
Read Also: The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
阅读更多：Ketamir-2的潜力：用于精神健康障碍和神经病痛的更安全治疗，预计在年底前提交IND申请
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
免费订阅我们的新闻简报以获得Benzinga对大麻行业和市场的独家分析和头条新闻。如果你对这个行业很认真，不能错过。
Ketamine Clinics And Treatments
氯胺酮诊所和治疗
Ketamine, originally an anesthetic, has gained significant attention in recent years for its off-label use in treating mental health conditions such as depression, PTSD, and treatment-resistant depression (TRD). The rise in ketamine assisted therapies is largely due to its rapid-acting properties, which offer relief where traditional antidepressants often fall short. As research progresses, treatments are becoming more refined, with new delivery methods like nasal sprays, topical creams and patient-controlled infusions enhancing accessibility and effectiveness.
氯胺酮起初是一种麻醉剂，近年来因其在治疗抑郁症、PTSD和难治性抑郁症(TRD)等精神健康状况方面的非标签使用而引起了广泛关注。氯胺酮辅助疗法的兴起主要归功于其快速作用的特性，能在传统抗抑郁药物效果不佳时提供缓解。随着研究的进展，治疗方法变得更加精细，新的给药方法如鼻喷剂、局部药膏和患者控制的输注等提高了可及性和有效性。
Photo: Courtesy of Sonis Photography via Shutterstock
图片：由 shutterstock 提供的 Sonis Photography 公司的图像。